Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

Jeffrey J. Crowley; Richard G. Langley; Kenneth B. Gordon; Andreas Pinter; Laura K. Ferris; Simone Rubant; Huzefa Photowala; Zhenyi Xue; Tianshuang Wu; Tianyu Zhan; Stefan Beeck; Megha Shah; Richard B. Warren

doi:10.1007/s13555-021-00679-6

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

Jeffrey J. Crowley, Richard G. Langley, Kenneth B. Gordon, Andreas Pinter, Laura K. Ferris, Simone Rubant, Huzefa Photowala, Zhenyi Xue, Tianshuang Wu, Tianyu Zhan, Stefan Beeck, Megha Shah, Richard B. Warren

Inernational Relations Division

科研成果: 期刊稿件 › 文章 › 同行评审

9 引用（Scopus）

源语言	英语
页（从-至）	561-575
页数	15
期刊	Dermatology and Therapy
卷	12
期	2
DOI	https://doi.org/10.1007/s13555-021-00679-6
出版状态	已出版 - 2月 2022

!!!ASJC Scopus Subject Areas

皮肤医学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1007/s13555-021-00679-6

其它文件与链接

引用此

Crowley, J. J., Langley, R. G., Gordon, K. B., Pinter, A., Ferris, L. K., Rubant, S., Photowala, H., Xue, Z., Wu, T., Zhan, T., Beeck, S., Shah, M., & Warren, R. B. (2022). Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatology and Therapy, 12(2), 561-575. https://doi.org/10.1007/s13555-021-00679-6

Crowley, JJ, Langley, RG, Gordon, KB, Pinter, A, Ferris, LK, Rubant, S, Photowala, H, Xue, Z, Wu, T, Zhan, T, Beeck, S, Shah, M & Warren, RB 2022, 'Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study', Dermatology and Therapy, 卷 12, 号码 2, 页码 561-575. https://doi.org/10.1007/s13555-021-00679-6

@article{5c76c7dc02324856afe1eb0918f05b03,

title = "Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study",

keywords = "Biologics, Prior psoriasis treatment, Psoriasis, Risankizumab, Secukinumab, Subgroup analysis, Weight",

author = "Crowley, {Jeffrey J.} and Langley, {Richard G.} and Gordon, {Kenneth B.} and Andreas Pinter and Ferris, {Laura K.} and Simone Rubant and Huzefa Photowala and Zhenyi Xue and Tianshuang Wu and Tianyu Zhan and Stefan Beeck and Megha Shah and Warren, {Richard B.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = feb,

doi = "10.1007/s13555-021-00679-6",

language = "English",

volume = "12",

pages = "561--575",

journal = "Dermatology and Therapy",

issn = "2193-8210",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis

T2 - Subgroup Analysis from the IMMerge Study

AU - Crowley, Jeffrey J.

AU - Langley, Richard G.

AU - Gordon, Kenneth B.

AU - Pinter, Andreas

AU - Ferris, Laura K.

AU - Rubant, Simone

AU - Photowala, Huzefa

AU - Xue, Zhenyi

AU - Wu, Tianshuang

AU - Zhan, Tianyu

AU - Beeck, Stefan

AU - Shah, Megha

AU - Warren, Richard B.

PY - 2022/2

Y1 - 2022/2

KW - Biologics

KW - Prior psoriasis treatment

KW - Psoriasis

KW - Risankizumab

KW - Secukinumab

KW - Subgroup analysis

KW - Weight

UR - http://www.scopus.com/inward/record.url?scp=85123243722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123243722&partnerID=8YFLogxK

U2 - 10.1007/s13555-021-00679-6

DO - 10.1007/s13555-021-00679-6

M3 - Article

AN - SCOPUS:85123243722

SN - 2193-8210

VL - 12

SP - 561

EP - 575

JO - Dermatology and Therapy

JF - Dermatology and Therapy

IS - 2

ER -

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此